How to buy Abcam stock (Abcam)

Abcam is a biotechnology business based in the US. Abcam shares (ABCM) are listed on the NASDAQ and all prices are listed in US Dollars. Abcam employs 1,760 staff and has a trailing 12-month revenue of around $379.7 million.

Our top picks for where to buy Abcam PLC stock

Buy Abcam stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Abcam stock price (NASDAQ: ABCM)

Use our graph to track the performance of ABCM stocks over time.

Abcam shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$23.39
200-day moving average more info button	$20.52
Wall St. target price	$1,902.05
PE ratio more info button	2399
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.01

Is it a good time to buy Abcam stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Abcam stock undervalued or overvalued?

Valuing Abcam stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcam's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abcam's P/E ratio

Abcam's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2399x. In other words, Abcam shares trade at around 2399x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Abcam's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Gilead Sciences (GILD.US): 1,007.67
• GlaxoSmithKline PLC ADR (GSK.US): 21.88
• Novartis AG ADR (NVS.US): 16.90
• Regeneron Pharmaceuticals (REGN.US): 17.67

Abcam's EBITDA

Abcam's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $106 million.

The EBITDA is a measure of a Abcam's overall financial performance and is widely used to measure a its profitability.

To put Abcam's EBITDA into context you can compare it against that of similar companies.

• Gilead Sciences (GILD.US): USD$13.9 billion
• GlaxoSmithKline PLC ADR (GSK.US): USD$9.3 billion
• Novartis AG ADR (NVS.US): USD$21 billion
• Regeneron Pharmaceuticals (REGN.US): USD$4.6 billion

Abcam financials

Revenue TTM	$379.7 million
Operating margin TTM	18.31%
Gross profit TTM	$270.5 million
Return on assets TTM	4.36%
Return on equity TTM	0.35%
Profit margin	0.66%
Book value	$3.14
Market Capitalization more info button	$5.5 billion

TTM: trailing 12 months

Abcam share dividends

We're not expecting Abcam to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.4% forward annual dividend yield)
• GlaxoSmithKline PLC ADR (GSK.US) (4.64% forward annual dividend yield)
• Novartis AG ADR (NVS.US) (3.86% forward annual dividend yield)

Have Abcam's shares ever split?

Abcam's shares were split on a 5:1 basis on 30 November 2010 . So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Abcam shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Abcam shares which in turn could have impacted Abcam's share price.

Abcam share price volatility

Over the last 12 months, Abcam's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcam's is 0.863. This would suggest that Abcam's shares are less volatile than average (for this exchange).

To put Abcam's beta into context you can compare it against those of similar companies.

• Gilead Sciences (GILD.US): 0.192
• GlaxoSmithKline PLC ADR (GSK.US): 0.33
• Novartis AG ADR (NVS.US): 0.505
• Regeneron Pharmaceuticals (REGN.US): 0.142

Abcam overview

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.

Frequently asked questions

null
What percentage of Abcam is owned by insiders or institutions?
Currently 6.443% of Abcam shares are held by insiders and 88.218% by institutions. How many people work for Abcam?
Latest data suggests 1,760 work at Abcam. When does the fiscal year end for Abcam?
Abcam's fiscal year ends in June. Where is Abcam based?
Abcam's address is: Discovery Drive, Cambridge, United Kingdom, CB2 0AX What is Abcam's ISIN number?
Abcam's international securities identification number is: US0003802040